Neurophet, ReadyCure developing AI-powered dementia treatment device and more APAC collab briefs
12 Feb 2024
Radiation Therapy
Preview
Source: mobihealthnews
[Left-Right] ReadyCure CEO Won-gyu Jeong and Neurophet CEO Jun-gil Bin during the signing of a business deal
Photo courtesy of Neurophet
Neurophet AI to integrate with upcoming Alzheimer's treatment device
Based on a press statement, Neurophet will be integrating its AI solution, Neurophet AQUA, to support brain image analysis in Helaxon. The AI-based software can analyse and detect white matter degeneration in brain MRI scans of patients with Alzheimer's disease.
ReadyCure will use this capability alongside its use of digital X-ray to deliver low-dose radiation to treat dementia, particularly Alzheimer's disease.
New cardiac ultrasound AI coming to Korea
Digital health company SELVAS Healthcare will be bringing to South Korea an AI-based heart ultrasound technology from Israel.
It has partnered with UltraSight to help it secure regulatory approval in the country for its AI guidance software while also having exclusive distribution rights to the product. UltraSight offers an AI solution that assists in acquiring cardiac ultrasound images at the point of care. The Israeli company also has a long-term plan to enter other Asian markets, particularly in Southeast Asia.
Latest healthcare blockchain offering for patient data safety
Verida, a provider of decentralised data networks based in Singapore, has teamed up with Swiss company Partisia Blockchain to offer a new integrated tech solution for securing patient health data.
Their new privacy tech stack combines Verida's decentralised network for data storage and Partisia's advanced multiparty computation technology to enable users to control access to their data by removing centralised data storage in the process.
It also allows patients to securely contribute to healthcare research while maintaining total privacy and complete control of their data, a press statement noted.
Tags: Neurophet, ReadyCure, South Korea, SELVAS, UltraSight, Verida, Partisia Blockchain, Singapore
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.